1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Rare Setback For Merck & Co And AstraZeneca’s Keytruda-Lynparza Combo In Prostate Cancer

All-Comers Approach Disappoints

 
• By Andrew McConaghie

Metastatic prostate cancer continues to evade the checkpoint inhibitor class but Merck is not giving up on an area where overall survival remains limited.

Merck 1200
Merck and AstraZeneca's partnership has been successful but metastatic prostate cancer has again proven resistant to combination therapy • Source: Alamy

Merck & Co and AstraZeneca are to halt a Phase III study of cancer blockbusters Keytruda and Lynparza as a third-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after the combination failed to show benefits to patients.

The result is a rare setback for Keytruda and Lynparza, which have grown steadily to lead their respective PD-1/PD-L1 and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.